Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines - Wikidata - wikimedia - TriplyDB

Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

http://www.wikidata.org/entity/Q24633053

about

Pentasaccharides for the treatment of deep vein thrombosis Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism Outpatient versus inpatient treatment for acute pulmonary embolism Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis Assessing bleeding risk in patients taking anticoagulants Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Risk impact of edoxaban in the management of stroke and venous thromboembolism Anticoagulants for the prevention and treatment of catheter-related thrombosis in adults and children on parenteral nutrition: a systematic review and critical appraisal Management of bleeding in patients treated with direct oral anticoagulants Effective management of venous thromboembolism in the community: non-vitamin K antagonist oral anticoagulants Comparative risk impact of edoxaban in the management of stroke and venous thromboembolism Direct-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine Physicians Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis Edoxaban in venous thromboembolism and stroke prevention: an appraisal Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date Considerations for long-term anticoagulant therapy in patients with venous thromboembolism in the novel oral anticoagulant era Venous thromboembolism in Latin America: a review and guide to diagnosis and treatment for primary care Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis The evolution of anticoagulant therapy Transitions in the Prophylaxis, Treatment and Care of Patients with Venous Thromboembolism Trousseau's syndrome: cancer-associated thrombosis Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence Assessing the risk of recurrent venous thromboembolism--a practical approach Nonsurgical Therapeutic Options in Portal Vein Thrombosis Venous thromboembolism in the ICU: main characteristics, diagnosis and thromboprophylaxis Critical appraisal of dabigatran in the treatment of deep vein thrombosis and pulmonary embolism Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran Anticoagulants in cancer Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation Recurrent venous thromboembolism: what is the risk and how to prevent it Major bleeding during secondary prevention of venous thromboembolism in patients who have completed anticoagulation: a systematic review and meta-analysis Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications Which patients with venous thromboembolism should receive non-vitamin K antagonist oral anticoagulants? The majority Venous thromboembolism in cancer patients: an underestimated major health problem Supplemental patient education for patients taking oral anticoagulants: systematic review and meta-analysis

P2860

Q24186811-654AD41B-9745-47AC-BE50-5AD7F52DDFA1 Q24187205-253BA3CF-CA97-4BD1-8CA4-3CE8AD0CB88B Q24187901-5015EABD-1FDF-4935-9FB5-2F105E6C43E0 Q24197581-4CDD0C0E-3575-4772-AEB8-6B261951A803 Q24200864-E77E7D86-2E74-4C8A-9DFD-2A7CD5C4F12A Q24200867-57253872-94B9-465D-9FC7-D802C29A75DC Q24619070-5D0273BE-0693-4ABD-932C-762261B9750B Q24632927-780DD1AF-2104-48B2-BA31-830E30EAFA9A Q24632951-9EB3A630-770B-4394-AFE3-7FAC393BE12E Q24632982-F00504D6-B6F6-404B-8F20-97935482BBED Q24633090-943C0127-37B8-42F0-8F2C-871B47D43BEC Q26738846-67E7A255-77D4-4BC7-885A-A982EA1C0A18 Q26739939-349EC885-BF49-4B90-B0F2-6CB73E34CBB6 Q26740258-862DFF4F-8AD4-4F8E-8F26-29514FF70705 Q26746213-A8BF9CE1-0396-4F09-9348-D02B4938FADD Q26746233-3C4F98DD-C1BC-41E0-8A98-BDE33478A616 Q26746917-26230174-0588-4039-B58F-478994381BAC Q26749273-0A2C1779-9B16-472F-BC7B-5A49FE5D587C Q26751263-0CD15EDB-3DCA-4B3C-992F-C83775826D0D Q26764874-86051C6A-EB93-412C-9AF8-9DF9F8778A7D Q26765299-25E1E88E-9FAA-4979-AE51-670FE16F2B78 Q26766262-597734EB-F245-43E5-A9FC-BAB12F54F088 Q26771581-165FB074-A8EC-413D-A840-E4B4C30D51FD Q26771859-CCC9036D-022F-4544-9A5F-2042F8D80C8C Q26775157-787DEC20-303F-4D7B-A983-76268AE8196F Q26778607-5683ECD4-3341-48A5-9C97-44CB588A85C5 Q26782483-686CBC25-D552-499B-8AC1-830D8D4BDD6F Q26796430-DB654EBA-BC12-4DBC-B70B-66127B55A383 Q26796510-F1E0A124-5FAF-490D-8681-A1166A965D71 Q26797444-93E349B3-C253-4F29-B7DA-BF9D55892603 Q26799691-7FE536D8-A488-4BF0-BE67-1BE3A51D75F8 Q26799710-BD02FC0E-FC08-4737-98A2-4E84A625C0CA Q26825228-D0285DB1-8EA8-49DA-8DB1-A91E703099BD Q26825608-2298E827-DD01-49BF-8521-536809B15A36 Q26826847-1E966F9C-F8A3-438C-8639-D45A85915962 Q26828750-127BBED6-F074-4684-9170-4AD85EC04F9F Q26828817-ED00CD78-B03A-4BE7-B722-D407129E10F2 Q26849407-6CCBA501-305B-4E06-B334-9C78FEEE140F Q26852015-41CCDF64-975B-4C52-AC03-B3ED298B52D3 Q26852661-DD5A0B7C-9791-4F3F-8F11-F879BFD54EF2

P2860

Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

http://www.wikidata.org/entity/Q24633053

description

2012 nî lūn-bûn

@nan

2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Antithrombotic therapy for VTE ...... d Clinical Practice Guidelines

@ast

Antithrombotic therapy for VTE ...... d Clinical Practice Guidelines

@en

Antithrombotic therapy for VTE ...... d Clinical Practice Guidelines

@nl

type

label

Antithrombotic therapy for VTE ...... d Clinical Practice Guidelines

@ast

Antithrombotic therapy for VTE ...... d Clinical Practice Guidelines

@en

Antithrombotic therapy for VTE ...... d Clinical Practice Guidelines

@nl

prefLabel

Antithrombotic therapy for VTE ...... d Clinical Practice Guidelines

@ast

Antithrombotic therapy for VTE ...... d Clinical Practice Guidelines

@en

Antithrombotic therapy for VTE ...... d Clinical Practice Guidelines

@nl

P1433

Q24633053-AFD35516-EC65-4328-B81E-785A819CF8F3

P1476

Q24633053-B693034A-F5C3-4903-849B-DE42F268A935

P2093

Q24633053-0A6E0BF1-8594-4445-B72C-57A800F4C53D

Q24633053-1DE450CE-3A21-4EA8-827D-69C41F9814ED

Q24633053-5891C6E5-AC91-4E00-B49B-67D21CFB3C0D

Q24633053-63C9B2D3-64D8-496E-929C-1F5D3826C871

Q24633053-87178537-DDF5-4A91-9C85-5D435C03E18B

Q24633053-8B423619-5DBB-45B6-B92C-CD8265A9C761

Q24633053-8EAB26BB-8B5B-4A76-81A9-016657F9280C

Q24633053-8FE16E0B-44A4-4C6E-ABB1-2488948868BA

Q24633053-BEDFBA7C-E37C-4E21-A2FD-42A2D549D372

Q24633053-CBC2D81A-647C-4C93-994F-806E41D3A501

P2860

Q24633053-0028D1E8-9CC8-4CC9-90E0-EAA07A5C1AA3

Q24633053-0108E8B6-7AEB-4E23-A635-B5BFE9ACA552

Q24633053-02298F2F-FEC5-4E8B-8E48-3723251D98A5

Q24633053-02CFC2DE-9E01-4B57-A520-88267D9B23B0

Q24633053-0395793A-7317-49E9-9D79-2C62AF1E60BA

Q24633053-0786B8FA-15F2-437C-BCF2-2836BC24F4B5

Q24633053-078E20CC-6BC1-408F-9720-6E1F080E39E4

Q24633053-086E5B10-3D57-488B-8AED-5F30A7082498

Q24633053-087C9597-34F6-4ED6-87D3-FCAE3A24807C

Q24633053-0882164D-5D77-4C2F-BD9D-447BC18C4198

P304

Q24633053-BD64EAC9-C284-4FB0-BF3E-1E6BE8BE2C57

P31

Q24633053-6950501A-0C2B-4B02-AD7B-A3CC295EF865

P3181

Q24633053-95E31D0B-5E24-46FE-890C-721007AADAA9

P356

Q24633053-7624F181-3695-4345-BD73-DD16D1039AED

P407

Q24633053-3CE972ED-487F-45CF-B133-12D0F4933E00

P433

Q24633053-95B8394D-EE79-4156-9BA8-6C1272FDEF9C

P478

Q24633053-5DBA262F-401D-480C-ABF2-E1B2BDBB8D82

P50

Q24633053-C3B9ACD5-4961-41F3-A89D-E27937412188

P577

Q24633053-BC1808D7-B75D-4010-8751-B40413CDCAE8

P5875

Q24633053-CDD85F73-CB6D-4630-9037-44A6B2B9C3CA

P698

Q24633053-1A203F48-9D57-452D-9760-E7DCEEE98BF9

P921

Q24633053-EF50B86C-798A-4971-B838-68A04772035A

P932

Q24633053-5D0A6001-7B8C-428C-AA4A-10577A47ADD0

P3181

P356

P1433

P1476

Antithrombotic therapy for VTE ...... d Clinical Practice Guidelines

@en

P2093

Anthony J Comerota

http://www.w3.org/2001/XMLSchema#string

Clive Kearon

http://www.w3.org/2001/XMLSchema#string

Francesco Dentali

http://www.w3.org/2001/XMLSchema#string

Henri Bounameaux

http://www.w3.org/2001/XMLSchema#string

Mark Crowther

http://www.w3.org/2001/XMLSchema#string

Michael E Nelson

http://www.w3.org/2001/XMLSchema#string

Michael K Gould

http://www.w3.org/2001/XMLSchema#string

Paolo Prandoni

http://www.w3.org/2001/XMLSchema#string

Philip S Wells

http://www.w3.org/2001/XMLSchema#string

Samuel Z Goldhaber

http://www.w3.org/2001/XMLSchema#string

P2860

Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism

Home versus in-patient treatment for deep vein thrombosis

Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism

Thrombolytic therapy for pulmonary embolism

Once versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolism

Treatment for superficial thrombophlebitis of the leg

Thrombolysis for acute deep vein thrombosis

Compression therapy for treating stage I and II (Widmer) post-thrombotic syndrome

Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

P304

e419S-94S

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

543407

http://www.w3.org/2001/XMLSchema#string

P356

10.1378/CHEST.11-2301

http://www.w3.org/2001/XMLSchema#string

P407

P433

2 Suppl

http://www.w3.org/2001/XMLSchema#string

P478

141

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221815438

http://www.w3.org/2001/XMLSchema#string

P698

22315268

http://www.w3.org/2001/XMLSchema#string

P921

P932

3278049

http://www.w3.org/2001/XMLSchema#string